MENU
FEMY
AS OF
Feb 3, 04:59 PM (EDT)
Price
$0.53
Change
-$0.12 (-18.46%)
Capitalization
30.7M
51 days until earnings call
Intraday BUY SELL Signals
+Compare
FEMY
Stock ticker: NASDAQ
AS OF
Feb 3, 04:59 PM (EDT)
Price
$0.53
Change
-$0.12 (-18.46%)
Capitalization
30.7M

FEMY stock forecast, quote, news & analysis

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas... Show more

FEMY
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. FEMY showed earnings on November 14, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for FEMY with price predictions
Feb 02, 2026

FEMY's RSI Oscillator dives oversold zone

The RSI Indicator for FEMY moved into overbought territory on February 02, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FEMY advanced for three days, in of 173 cases, the price rose further within the following month. The odds of a continued upward trend are .

FEMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FEMY as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FEMY turned negative on January 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

FEMY moved below its 50-day moving average on December 24, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for FEMY crossed bearishly below the 50-day moving average on December 26, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FEMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for FEMY entered a downward trend on February 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.739) is normal, around the industry mean (11.444). P/E Ratio (0.000) is within average values for comparable stocks, (149.532). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.462). FEMY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (7.386) is also within normal values, averaging (110.694).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. FEMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FEMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 11.42B. The market cap for tickers in the group ranges from 246 to 176.09B. ISRG holds the highest valuation in this group at 176.09B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -2%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 25%. TUTH experienced the highest price growth at 107%, while GCTK experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 9%. For the same stocks of the Industry, the average monthly volume growth was 16% and the average quarterly volume growth was -11%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 67
Price Growth Rating: 61
SMR Rating: 78
Profit Risk Rating: 94
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
FEMY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
N/A
Address
3950 Johns Creek Court
Phone
+1 770 500-3910
Employees
34
Web
https://www.femasys.com